Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving vinorelbine together with bevacizumab may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving vinorelbine together with bevacizumab works in treating older patients with stage III or stage IV non-small cell lung cancer.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Oct 29, 2024 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- University of Rochester
- Interventions being studied
- Biological: bevacizumab; Drug: vinorelbine tartrate
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed non-squamous, non-small cell lung cancer (NSCLC)
- Stage IIIB (any T, N3, M0 OR T4, any N, M0, OR pleural effusion) OR stage IV (any T, any N, M1) disease
- Mixed tumors will be categorized by the predominant cell type unless small cell elements are present, in which case the patient is ineligible
- Measurable or evaluable disease
- No lung carcinoma of squamous cell histology or any histology in close proximity to a major vessel or cavitation
- No known brain metastases, even if treated PATIENT CHARACTERISTICS:
- No other malignancies within the past 5 years except nonmelanoma skin cancer
- ECOG performance status 0-1
- Absolute neutrophil count ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Bilirubin ≤ 1.5 mg/dL
- Transaminases ≤ 5 times upper limit of normal (ULN)
- Creatinine ≤ 1.5 times ULN
- Urine protein:creatinine ratio \< 1
- INR ≤ 1.5
- PTT normal
- No prior ileus or neuropathy compromising use of vinorelbine ditartate
- Patients with a history of hypertension must be well controlled (blood pressure \< 150/100 mm Hg) on a stable regimen of antihypertensive therapy
- None of the following conditions:
- Unstable angina
- New York Heart Association grade II-IV congestive heart failure
- Myocardial infarction within the past 6 months
- Stroke within the past 6 months
- Evidence of bleeding diathesis or coagulopathy
- Clinically significant peripheral vascular disease
- Serious, nonhealing wound, ulcer, or bone fracture
- History of hemoptysis (bright red blood ≥ ½ teaspoon)
- No significant traumatic injury within the past 4 weeks
- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
- Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY:
- No prior chemotherapy for NSCLC
- More than 4 weeks since prior and no concurrent participation in another experimental drug study
- More than 4 weeks since prior immunotherapy, hormonal therapy, or radiotherapy and recovered
- More than 28 days since prior major surgical procedure or open biopsy
- No anticipation of need for major surgery during course of trial
- More than 7 days since prior minor surgical procedures (e.g., fine-needle aspiration or core biopsy)
- No concurrent full-dose anticoagulation therapy for thromboembolic disease, aspirin (\> 325 mg/day), or nonsteroidal anti-inflammatory drugs
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- James P. Wilmot Cancer Center at University of Rochester Medical CenterRochester, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 29, 2024. Always confirm current availability with the study team.